- AU$408.64m
- AU$273.42m
- 29
- 16
- 33
- 14
Annual income statement for Imugene, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.18 | 10.8 | 18.6 | 38 | 39.8 |
Operating Profit | -8.18 | -10.8 | -18.6 | -38 | -39.8 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -7.78 | -10.5 | -18.5 | -37.9 | -37.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.78 | -10.5 | -18.5 | -37.9 | -37.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.78 | -10.5 | -18.5 | -37.9 | -37.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.78 | -10.5 | -18.5 | -37.9 | -37.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.003 | -0.004 | -0.007 | -0.006 |